{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:02:24Z","timestamp":1788397344855,"version":"build-2803163510"},"reference-count":258,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":125,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0001"],"award-info":[{"award-number":["RD21\/0005\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.nefroe.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T15:50:42Z","timestamp":1684511442000},"page":"6-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis"],"prefix":"10.1016","volume":"43","author":[{"given":"Jorge E.","family":"Rojas-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Espino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fern\u00e1ndez-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Fulladosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mac\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F. Quintana","family":"Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"789","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0015","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.2010.13","article-title":"Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system","volume":"77","author":"Yu","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2215\/CJN.01880216","article-title":"Lupus podocytopathy: a distinct entity","volume":"11","author":"Bomback","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.ackd.2019.06.002","article-title":"Classification of lupus nephritis; time for a change?","volume":"26","author":"Stokes","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.ackd.2019.08.015","article-title":"The kidney biopsy in systemic lupus erythematosus: a view of the past and a vision of the future","volume":"26","author":"Ayoub","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000511268","article-title":"Update on lupus nephritis: looking for a new vision","volume":"145","author":"Morales","year":"2021","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.nefroe.2023.05.006_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ckj\/sfx093","article-title":"Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis","volume":"11","author":"Wilson","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semarthrit.2019.06.002","article-title":"Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies","volume":"49","author":"Leatherwood","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0075","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/ndt\/gft272","article-title":"The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients","volume":"28","author":"Pagni","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"10.1016\/j.nefroe.2023.05.006_bib0080","doi-asserted-by":"crossref","first-page":"e7099","DOI":"10.1097\/MD.0000000000007099","article-title":"The value of repeat biopsy in lupus nephritis flares","volume":"96","author":"Narv\u00e1ez","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.kint.2018.06.026","article-title":"Repeat kidney biopsy for lupus nephritis: an important step forward","volume":"94","author":"Nachman","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0090","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/0961203313518625","article-title":"The value of repeat kidney biopsy in quiescent Argentine lupus nephritis patients","volume":"23","author":"Alvarado","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0105","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.md.0000104742.42401.e2","article-title":"The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among \u201cHispanics.\u201d","volume":"83","author":"Pons-Estel","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0125","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0130","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000\u20132004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0145","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0150","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0155","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJMra1604481","article-title":"Hematuria in adults","volume":"385","author":"Ingelfinger","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0165","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0961203306070002","article-title":"Further description of early clinically silent lupus nephritis","volume":"15","author":"Zabaleta-Lanz","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0170","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/106904","article-title":"The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy","volume":"2015","author":"Moroni","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2009.04746.x","article-title":"Anti-C1q autoantibodies in lupus nephritis","volume":"1173","author":"Sinico","year":"2009","journal-title":"Ann New York Acad Sci"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0961203310379871","article-title":"Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares","volume":"20","author":"Matrat","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0185","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/ard.2008.094508","article-title":"Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis","volume":"68","author":"Moroni","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.nefroe.2023.05.006_bib0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0614-5","article-title":"Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up","volume":"17","author":"Gerhardsson","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0200","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.kint.2017.04.029","article-title":"Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy","volume":"92","author":"Turner-Stokes","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.ackd.2019.09.001","article-title":"Utilization of biomarkers in lupus nephritis","volume":"26","author":"Caster","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0210","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2023.05.006_bib0215","first-page":"1","article-title":"Diagnosis and treatment of lupus nephritis. Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN)","volume":"32","author":"Ruiz Irastorza","year":"2012","journal-title":"Nephrology"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0225","article-title":"Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome","volume":"2","author":"Dall\u2019Era","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0230","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.130005","article-title":"Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment","volume":"41","author":"Touma","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2016.11.019","article-title":"Prognostic significance of repeat biopsy in lupus nephritis: histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death","volume":"185","author":"Arriens","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0961203315606985","article-title":"Renal flare prediction and prognosis in lupus nephritis Hispanic patients","volume":"25","author":"Mej\u00eda-Vilet","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/0961203305lu2081oa","article-title":"Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine","volume":"14","author":"Chan","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0250","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0255","first-page":"2449","article-title":"Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study","volume":"28","author":"Ghaussy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1067\/mjd.2000.103635","article-title":"Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment","volume":"42","author":"Jewell","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0265","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/acr.21966","article-title":"Association of smoking with cutaneous manifestations in systemic lupus erythematosus","volume":"65","author":"Bourr\u00e9-Tessier","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0270","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3899\/jrheum.090403","article-title":"Cigarette smoking and cutaneous damage in systemic lupus erythematosus","volume":"36","author":"Turchin","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0275","first-page":"1215","article-title":"Cigarette smoking and disease activity in systemic lupus erythematosus","volume":"30","author":"Ghaussy","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0b013e32801494e3","article-title":"The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Str\u00f6mbeck","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0285","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/art.21605","article-title":"Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus","volume":"53","author":"Carvalho","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/ard.50.7.463","article-title":"Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus","volume":"50","author":"Walton","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0295","first-page":"1551","article-title":"The clinical effect of dietary supplementation with omega-3 fish oils and\/or copper in systemic lupus erythematosus","volume":"31","author":"Duffy","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0300","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2007.077156","article-title":"A randomized interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus","volume":"67","author":"Wright","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0305","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.autrev.2012.10.005","article-title":"Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus","volume":"12","author":"Sigges","year":"2013","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0310","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0315","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s11255-011-0110-z","article-title":"Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomized, controlled trial","volume":"44","author":"Lizakowski","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0320","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000290","article-title":"Mineralocorticoid antagonists in chronic kidney disease","volume":"26","author":"Dhaybi","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0325","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0330","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0335","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000213","article-title":"Early proteinuria response: a valid real-life situation predictor of long-term renal lupus outcome in an ethnically diverse group with severe biopsy-proven nephritis?","volume":"4","author":"Ugolini-Lopes","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0340","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0345","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0350","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0360","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","article-title":"Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0365","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0370","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0375","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0961203317726376","article-title":"Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis","volume":"27","author":"Pakchotanon","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0380","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","article-title":"Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort","volume":"27","author":"Mok","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0385","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10067-014-2527-0","article-title":"Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study","volume":"33","author":"Pokroy-Shapira","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0390","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0395","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0961203319890007","article-title":"Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hyd roxychloroquine","volume":"29","author":"Lee","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0400","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001299","article-title":"Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)","volume":"6","author":"Re\u00e1tegui-Sokolova","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0405","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0410","article-title":"Prescribing patterns of hydroxychloroquine and corticosteroids among lupus patients after new-onset end-stage renal disease","author":"Broder","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0415","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0420","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","article-title":"Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions","volume":"30","author":"Ugarte","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0425","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2023.05.006_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00393-020-00785-4","article-title":"Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review","volume":"80","author":"Fiehn","year":"2021","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0435","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","article-title":"The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Tseng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0440","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","article-title":"Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists","volume":"275","author":"Stahn","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0445","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0450","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0455","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0460","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0465","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0470","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0475","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0961203319842924","article-title":"Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies","volume":"28","author":"Dall\u2019Era","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0480","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/acr.21558","article-title":"Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus","volume":"64","author":"Mina","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0485","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0490","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0495","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0500","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0505","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ajog.2005.02.063","article-title":"Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus","volume":"192","author":"Chakravarty","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0510","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomized clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0515","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-75-2-165","article-title":"Cyclophosphamide in lupus nephritis: a controlled trial","volume":"75","author":"Steinberg","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0520","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0525","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0530","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0535","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0540","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.02670409","article-title":"Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option","volume":"4","author":"McKinley","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0545","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/art.10138","article-title":"Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine","volume":"46","author":"Mok","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0550","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJM198806023182203","article-title":"Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus","volume":"318","author":"McCune","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0555","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0560","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0092-8674(00)81275-1","article-title":"Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid","volume":"85","author":"Sintchak","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0565","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajmg.a.35223","article-title":"Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services","volume":"158A","author":"Hoeltzenbein","year":"2012","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0570","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0575","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0580","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0585","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0590","series-title":"Basic and Clinical Pharmacology","first-page":"986","article-title":"Immunopharmacology","author":"Lake","year":"2018"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0595","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.13761119","article-title":"The evolving role of calcineurin inhibitors in treating lupus nephritis","volume":"15","author":"Peleg","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0600","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/ijms22031263","article-title":"Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis","volume":"22","author":"Rafael-Vidal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0605","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/ndt\/gfab022","article-title":"Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE","volume":"37","author":"van Gelder","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0610","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/rheumatology\/37.2.217","article-title":"Clinical efficacy of cyclosporin to neoral in the treatment of pediatric lupus nephritis with heavy proteinuria","volume":"37","author":"Fu","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0615","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0620","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5414\/CN109325","article-title":"Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus","volume":"89","author":"Yang","year":"2018","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0625","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0630","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0640","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/0961203312448105","article-title":"Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study","volume":"21","author":"Wang","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0645","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0650","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/ndt\/gfr484","article-title":"Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis","volume":"27","author":"Li","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0655","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomized controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0660","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomized controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0665","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0670","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0675","doi-asserted-by":"crossref","first-page":"365","DOI":"10.18433\/jpps30526","article-title":"Multitarget therapy: an effective and safe therapeutic regimen for lupus nephritis","volume":"22","author":"Zhou","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0680","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomized, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.nefroe.2023.05.006_bib0685","article-title":"Principles of immunosuppression in the management of kidney disease: core curriculum 2022","volume":"S0272-6386","author":"Kant","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0690","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.080335","article-title":"Current therapies for lupus nephritis in an ethnically heterogeneous cohort","volume":"36","author":"Rivera","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0695","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0700","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41436-019-0448-7","article-title":"Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry","volume":"21","author":"Schaeffeler","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0705","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/TP.0b013e3182247b45","article-title":"Gout and transplantation: new treatment option-same old drug interaction","volume":"92","author":"Kaczmorski","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0710","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0715","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/rheumatology\/kes425","article-title":"Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine","volume":"52","author":"Fischer-Betz","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0720","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2019.03.004","article-title":"Refractory lupus nephritis: when, why and how to treat","volume":"18","author":"Kronbichler","year":"2019","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0725","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","article-title":"Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus","volume":"25","author":"Catapano","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0730","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0961203319828516","article-title":"Refractory lupus nephritis: a survey","volume":"28","author":"Weidenbusch","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0735","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203317749047","article-title":"Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus","volume":"27","author":"Iwata","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0740","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0745","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/0961203316641768","article-title":"Risk of clinical deterioration in patients with lupus nephritis receiving rituximab","volume":"25","author":"Manou-Stathopoulou","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0750","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomized, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0755","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/gfy267","article-title":"B-cell therapy in lupus nephritis: an overview","volume":"34","author":"Almaani","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0760","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/annrheumdis-2021-221270","article-title":"From sequential to combination and personalized therapy in lupus nephritis: moving towards a paradigm shift?","volume":"81","author":"Parodis","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0765","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","article-title":"Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review","volume":"16","author":"Sciascia","year":"2017","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0770","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0775","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learned?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0780","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0785","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.kint.2020.11.009","article-title":"Induction and maintenance therapy of lupus nephritis: an obituary","volume":"99","author":"Anders","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0790","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/j.ajkd.2020.11.003","article-title":"Belimumab in lupus nephritis: new trial results arrive during an exciting time for therapeutics","volume":"77","author":"Oliva-Damaso","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0795","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0800","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0805","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto","year":"2021","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.nefroe.2023.05.006_bib0815","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073766","article-title":"Advances in lupus nephritis pathogenesis: from bench to bedside","volume":"22","author":"Obri\u0219c\u0103","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0820","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0825","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0830","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.rdc.2018.06.003","article-title":"Nonproliferative forms of lupus nephritis: an overview","volume":"44","author":"Bomback","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0835","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1191\/0961203306lu2306rr","article-title":"The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans","volume":"15","author":"Teplitsky","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0840","doi-asserted-by":"crossref","first-page":"990","DOI":"10.15537\/smj.2018.10.22435","article-title":"The long-term outcomes and histological transformation in class II lupus nephritis","volume":"39","author":"Alsuwaida","year":"2018","journal-title":"Saudi Med J"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0845","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-021-05909-y","article-title":"Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0850","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","article-title":"Updates on the treatment of lupus nephritis","volume":"21","author":"Bomback","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0855","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.06720615","article-title":"Clinical-morphological features and outcomes of lupus podocytopathy","volume":"11","author":"Hu","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0860","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1191\/0961203306lu2264oa","article-title":"Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis","volume":"15","author":"Han","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0865","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.ackd.2019.08.011","article-title":"Lupus podocytopathy: an overview","volume":"26","author":"Oliva-Damaso","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0870","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.11751111","article-title":"Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease","volume":"7","author":"Salvatore","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0875","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1681\/ASN.2012121180","article-title":"Apolipoprotein L1 risk variants associated with systemic lupus erythematosus-associated collapsing glomerulopathy","volume":"24","author":"Larsen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0880","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/0961203315578766","article-title":"Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study","volume":"24","author":"Hu","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0885","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0890","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2004050350","article-title":"Glomerular podocytopathy in patients with systemic lupus erythematosus","volume":"16","author":"Kraft","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0895","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study","volume":"70","author":"Ruiz-Arruza","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0900","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0905","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0910","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0915","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve Studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0920","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0925","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study","volume":"61","author":"Walsh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0930","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0935","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0940","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0945","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0950","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.11467","article-title":"Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus","volume":"49","author":"Ward","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0955","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0960","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0961203309351541","article-title":"Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients","volume":"19","author":"Garcia-Carrasco","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0965","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0970","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0975","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0980","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0985","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-015-3166-9","article-title":"Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review","volume":"35","author":"Contis","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0990","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib0995","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1000","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1005","first-page":"459","article-title":"Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide","volume":"27","author":"Sur\u00eda","year":"2007","journal-title":"Nephrology"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.semnephrol.2015.08.010","article-title":"Pregnancy and lupus nephritis","volume":"35","author":"Kattah","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1586\/ecp.10.55","article-title":"Practical management of lupus nephritis in pregnancy and the puerperium","volume":"3","author":"Karim","year":"2010","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ndt\/gfn348","article-title":"Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome","volume":"24","author":"Imbasciati","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1025","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0961203312456893","article-title":"Pregnancy and renal outcomes in lupus nephritis: an update and guide to management","volume":"21","author":"Bramham","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/1744666X.2018.1476139","article-title":"Important considerations in pregnant patients with lupus nephritis","volume":"14","author":"Moroni","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1471-0528.2009.02473.x","article-title":"The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia","volume":"117","author":"Lynch","year":"2010","journal-title":"BJOG"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1040","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.ajog.2015.09.066","article-title":"Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study","volume":"214","author":"Kim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jaut.2016.06.012","article-title":"Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study","volume":"74","author":"Moroni","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1055","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1060","unstructured":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative, https:\/\/pubmed.ncbi.nlm.nih.gov\/28877866\/; 2022 [accessed August 2, 2022]."},{"key":"10.1016\/j.nefroe.2023.05.006_bib1065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","article-title":"Systemic lupus erythematosus in children and young people","volume":"23","author":"Charras","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jpeds.2018.01.045","article-title":"Childhood-onset systemic lupus erythematosus: a review and update","volume":"196","author":"Harry","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1075","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","article-title":"Kidney outcomes for children with lupus nephritis","volume":"36","author":"Oni","year":"2021","journal-title":"Pediatric Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1080","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1177\/09612033211044648","article-title":"Predictors for early readmission in patients hospitalized with new onset pediatric lupus nephritis","volume":"30","author":"Ah Guerra","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1085","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1177\/09612033211028658","article-title":"Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort","volume":"30","author":"Vazzana","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/0961203319836712","article-title":"Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis","volume":"28","author":"Smith","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","article-title":"An update on the management of childhood-onset systemic lupus erythematosus","volume":"23","author":"Trindade","year":"2021","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12969-021-00627-w","article-title":"Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE","volume":"19","author":"Gilbert","year":"2021","journal-title":"Pediatric Rheumatol Online J"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.41930","article-title":"International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis","volume":"74","author":"Chalhoub","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1110","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10157-017-1381-1","article-title":"Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy","volume":"21","author":"Tanaka","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00467-017-3583-x","article-title":"Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis","volume":"32","author":"Basu","year":"2017","journal-title":"Pediatric Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1120","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.rdc.2006.05.004","article-title":"Kidney disease in antiphospholipid syndrome","volume":"32","author":"friend","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal failure in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1135","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1140","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3899\/jrheum.170561","article-title":"Early Renin-angiotensin system blockade improved short-term and long-term renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy","volume":"45","author":"Yue","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1150","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1155","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/ndt\/gfq356","article-title":"What nephrologists need to know about antiphospholipid syndrome","volume":"25","author":"Alchi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1160","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2018-214559","article-title":"Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study","volume":"78","author":"Sciascia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1165","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1170","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1175","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(90)90295-O","article-title":"Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE","volume":"89","author":"Nossent","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1195","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12882-020-02083-2","article-title":"Systemic lupus erythematosus activity and hydroxychloroquine use before and after end-stage renal disease","volume":"21","author":"Salgado Guerrero","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1200","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14118","article-title":"Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: analysis of linked US registry and claims data","volume":"34","author":"Lentine","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0272-6386(99)70419-1","article-title":"Persistent lupus activity in end-stage renal disease","volume":"33","author":"Krane","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1210","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001263","article-title":"Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations","volume":"6","author":"Kostopoulou","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.transproceed.2013.11.080","article-title":"Outcome of lupus nephritis after entering into end-stage renal disease and comparison between different treatment modalities: a nationwide population-based cohort study in Taiwan","volume":"46","author":"Wu","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3904\/kjim.2011.26.1.60","article-title":"Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis","volume":"26","author":"Kang","year":"2011","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/M18-1570","article-title":"Renal Transplantation and survival among patients with lupus nephritis: a cohort study","volume":"170","author":"Jorge","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1230","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.22482","article-title":"Association of time to kidney transplantation with graft failure among US patients with end-stage renal disease due to lupus nephritis","volume":"67","author":"Plantinga","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1235","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","article-title":"Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis","volume":"77","author":"Moroni","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1240","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/0961203318770527","article-title":"Long-term survival of kidney grafts in lupus nephritis: a Mexican cohort","volume":"27","author":"Ramirez-Sandoval","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1245","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/0961203317696591","article-title":"Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience","volume":"26","author":"Naranjo-Escobar","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0961203317725591","article-title":"Renal outcome after kidney-transplantation in Korean patients with lupus nephritis","volume":"27","author":"Park","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1255","first-page":"140","article-title":"Renal transplantation in systemic lupus erythematosus: comparison of graft survival with other causes of end-stage renal disease","volume":"15","author":"Horta-Baas","year":"2019","journal-title":"Rheumatol Clin (Eng Ed)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1260","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.medcli.2018.09.016","article-title":"Kidney transplantation in systemic lupus erythematosus: outcomes and prognosis","volume":"153","author":"Pampa-Saico","year":"2019","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1265","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.kint.2016.02.014","article-title":"Long-term outcomes of end-stage kidney disease for patients with lupus nephritis","volume":"89","author":"Zhang","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1270","doi-asserted-by":"crossref","first-page":"581","DOI":"10.55563\/clinexprheumatol\/ri873i","article-title":"Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university center","volume":"40","author":"Mart\u00ednez-L\u00f3pez","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1275","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/09612033211028663","article-title":"Kidney transplantation outcomes in lupus nephritis: a 37-year single-center experience from Latin America","volume":"30","author":"Rodelo","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1280","doi-asserted-by":"crossref","first-page":"11611","DOI":"10.1038\/s41598-019-48070-y","article-title":"Outcome and prognosis of patients with lupus nephritis submitted to renal transplantation","volume":"9","author":"Albuquerque","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1285","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s10067-018-4115-1","article-title":"Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis","volume":"37","author":"Ntatsaki","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1290","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.semarthrit.2018.10.016","article-title":"Antiphospholipid antibodies and renal transplant: a systematic review and meta-analysis","volume":"48","author":"Ames","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2023.05.006_bib1295","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/TP.0000000000002510","article-title":"Antiphospholipid syndrome and renal allograft thrombosis","volume":"103","author":"Morales","year":"2019","journal-title":"Transplantation"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:51:07Z","timestamp":1761853867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":258,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2013251423000810"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.05.006","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2022.10.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}